AllDocs -> cancers

Copyright © 1998 by W.B. Saunders Company. All rights reserved. 320 A BASIC INFORMATION DESCRIPTION A malignancy beginning in the plasma cells of the bone marrow. Plasma cells normally produce antibodies to help destroy germs and protect against infection. With myeloma , this function becomes impaired, and the body cannot deal effectively with infection. It can affect the bone marrow of all bones but is most common in the thigh, back, pelvis or upper arms. It is most com- mon in men between ages 50 and 70. A recent report has found a virus associated with multiple myeloma . FREQUENT SIGNS AND SYMPTOMS • Pain in the affected bone. The pain is severe, boring and deep. If the bone collapses, pain spreads to other parts of the body. • Weight loss. • Symptoms of anemia, such as weakness, paleness, tiredness and breathlessness. CAUSES Unknown. ...

M ul ti ple myeloma is a clonal B-cell ma lig nancy usu ally seen in the el derly, with the me dium age at the time of di ag no sis be ing in the 7 th de cade of life. Its in ci dence among young in di vid u als was low (0.18% & 0.3%, re spec tively, in two large ret ro spec tive se ries). 1,2 The dis ease usu ally in volves bone mar row and bone. Al - though extramedullary plasmacytomas are not un usual, ce re bral plasmacytoma is rarely doc u mented. Young pa - tients (be low 30 years of age) seem to have more fa vor - able prog no sis and better sur vival. 2,3 We here with de - scribe a young pa tient of clin i cally ag gres sive myeloma with un usual man i fes ta tion and re view the lit er a ture. CASE RE PORT A 28-year-old man was ad mit ted to a gen eral hos pi - tal in June, 1999 be cause of se vere left knee joint ...

Multiple Myeloma 66 CANCER INCIDENCE AND MORTALITY IN NEW MEXICO, 1970-1996 Major Epidemiologic Features Multiple myeloma is a rare cancer that arises in the bone marrow and involves the plasma cells, a type of blood cell. Plasma cells play a critical role in the immune system by producing antibodies which normally circulate in the blood to ward off disease. The main characteristic of multiple myeloma is an overgrowth of malignant plasma cells that leads to the excess production of a specific antibody or component of the antibody. Multiple myeloma accounts for about 1% of all cancers diagnosed each year in the U.S., and about 2% of all annual cancer deaths. The prognosis for multiple myeloma is generally poor, with the probability of dying within five years of diagnosis at about 70%. Over the past several decades in the U.S., incidence has been rather stable while mortality has been slowly ...

Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States Linda Morris Brown 1, *, Gloria Gridley 1 , Linda M. Pottern 2,a , Dalsu Baris 1 , Christine A. Swanson 2,b , Debra T. Silverman 1 , Richard B. Hayes 1 , Raymond S. Greenberg 3,c , G. Marie Swanson 4,d , Janet B. Schoenberg 5 , Ann G. Schwartz 4 & Joseph F. Fraumeni, Jr 1 1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Executive Plaza South, Room 8026, 6120 Executive Blvd. MSC 7244, Bethesda, MD 20892-7244, USA; 2 National Cancer Institute, Bethesda MD, USA; 3 Rollins School of Public Health, Emory University, Atlanta, GA, USA; ...

myeloma Multiple Myeloma Jasmine Raley Jasmine Raley 4/11/02 2 What is Multiple Myeloma ? Multiple Myeloma is a form of cancer that is caused by malignant plasma cells. When plasma cells grow out of control they can produce a tumor. When these tumors grow in multiple sites they are referred to as multiple myeloma . Jasmine Raley 4/11/02 3 How is Multiple Myeloma Diagnosed? Laboratory tests of blood and urine. Bone x-rays. MRI Bone marrow samples. Jasmine Raley 4/11/02 4 Treatment Options High-dose chemotherapy. External beam radiation therapy. Jasmine Raley 4/11/02 5 Where can I find more information? http://www.cancer.org ...

U-266 Cell line U-266, human myeloma Transfection with Plasmid pEGFP-C1 (in bidistilled H 2 O) Electroporation buffer Eppendorf Hypoosmolar Electroporation Buffer (PH) Culture medium IMDM / 10 % FCS Cuvette Eppendorf, 2 mm gap width, 400 µl Temperature RT (20-25 °C) Reference Frau Pfeifer Universitätsklinikum Leipzig Molekulare Immunologie Johannisallee 30 D-04103 Leipzig Phone: +49 341 9725494 Fax: +49 341 9725489 1. Harvest the cells in the exponential growth phase and centrifuge them (for 5-10 minutes, 200 x g, at room temperature). 2. Resuspend the cells in IMDM / 0.5% FCS, determine the number of cells and centrifuge them (for 5-10 minutes, 200 x g, at room temperature). Remove supernatant. Note: The overall incubation time in the Eppendorf Electroporation Buffer must not exceed 30 minutes to guarantee a successful electroporation! ...

Page 1 of 3 of Instrument No.1 of 1995 Instrument No.1 of 1995 REVOKED Statement of Principles concerning MULTIPLE MYELOMA ICD CODE: 203.0 Veterans’ Entitlements Act 1986 subsection 196 B (2) 1. Being of the view that there is sound medical-scientific evidence that indicates that multiple myeloma and death from multiple myeloma can be related to operational service rendered by veterans, peacekeeping service rendered by members of Peacekeeping forces and hazardous service rendered by members of the Forces, the Repatriation Medical Authority determines, under subsection 196B(2) of the Veterans’ Entitlements Act 1986 , that the factors that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting multiple myeloma or death from multiple myeloma with the circumstances ...

10/22/00; Page 1 Multiple Myeloma (MM) (Monday, October 22, 2001) •B lymphoid malignancy characterized by the proliferation of malignant plasma cells •MM behaves as a solid tumor with a particular liking to disseminate in metastatic clusters in the marrow cavity. •MM originates in lymph nodes, first appear in the BM, and seldom in blood. •MM is a disease of the elderly; incidence in African-Americans is 2x of Caucasian. •The net result of MM is a devastating and dispiriting syndrome: •MM was first described in 1844 by Solly and was called "molitites ossium"; and then in 1845 by MacIntyre in London. Pathophysiology of Multiple Myeloma (MM) •Many problems associated with MM include: --plasma cell tumor that secrete substances; --synthesis of large quantities of monoclonal antibodies. •Most common presenting features in MM are: --bone pain; --hypercalcemia; --osteolysis; ...

Multiple Myeloma Statistical Tables and Highlights Multiple Myeloma - Number of Diagnosed Cancers and Average Annual Age-Adjusted Incidence Rates per 100,000 by Sex, Geographic Area, Race/Ethnicity, and Time Period, USA 1992-1996 and Colorado 1992-1996 and 1997 USA 1 1992-1996 Colorado 1992-1996 Colorado 1997 N Rate N Rate N Rate Male All Races 3292 5.5 434 5.5 103 6.1 White/Non-Hispanic 2592 5.1 356 5.2 85 5.8 White/Hispanic N/A N/A 47 6.9 9 5.8 Black 487 11.2 21 8.7 9 19.0 Female All Races 2954 3.7 339 3.3¢ 72 3.2 White/Non-Hispanic 2282 3.3 285 3.1 60 3.0 White/Hispanic N/A N/A 34 4.1 3 ...

MULTIPLE MYELOMA Pennsylvania Department of Health - Pennsylvania Cancer Incidence and Mortality 1994-1998 - Page 196 Incidence rates for multiple myeloma reported from the National Cancer Institute's SEER Program show the highest risks in blacks. The 1994-98 average annual age-adjusted incidence rates for Pennsylvania showed the same relationship. The rates for black male and black female residents were 11.4 and 7.9, respectively, versus 4.3 per 100,000 for all reported cases. Multiple myeloma accounted for 769 cancer cases diagnosed among Pennsylvania residents in 1998, the highest annual number reported during to ten-year period of 1989-1998. Annual age-adjusted incidence rates between 1989 and 1998 have generally been on the increase among all four sex/race groups. A distinct feature of multiple myeloma is the strong association with age. The average annual (1994-98) age-specific incidence rates were ...

NEOPLASIA The myeloma -associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells Zhihua Li, Yuan Xiao Zhu, Elizabeth E. Plowright, P. Leif Bergsagel, Marta Chesi, Bruce Patterson, Teresa S. Hawley, Robert G. Hawley, and A. Keith Stewart Translocations involving fibroblast growth factor receptor 3 (fgfr3) have been identi- fied in about 25% of patients with my- eloma. To directly examine the oncogenic potential of fgfr3, murine bone marrow (BM) cells were transduced with retroviral vectors containing either wild-type fgfr3 or an activated mutant form of the recep- tor, fgfr3-TD. Mice transplanted with FGFR3-TD–expressing BM developed a marked leukocytosis and lethal hemato- poietic cell infiltration of multiple tissues within 6 weeks of transplantation. Second- ary and tertiary recipients of spleen or BM from ...

Web Immagini Gruppi Directory News Novità! Ricerca avanzata Preferenze Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL Web La ricerca di - cache:5cIhd4QuvGIJ:static.cjp.com/gems/blood/Iida.pdf allintitle: myeloma filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti: - Assicurarsi che tutte le parole siano state digitate correttamente. - Provare con parole chiave diverse. - Provare con parole chiave più generiche. - Provare con un numero minore di parole chiave. ...

l del file contenuto in http://faculty-web.at.nwu.edu/nuds/ettlin/palate/PALATE.ppt . G o o g l e crea automaticamente la versione .html dei documenti durante la scansione del Web. Per inserire un segnalibro o un collegamento alla pagina, utilizzare il seguente URL: http://www.google.com/search?q=cache:IlW_upU1Ma4J:faculty-web.at.nwu.edu/nuds/ettlin/palate/PALATE.ppt+allintitle:+myeloma+filetype:pdf+OR++filetype:doc+OR+filetype:ppt+OR++filetype:xls+OR+filetype:rtf&hl=it&lr=lang_en Google non è collegato agli autori di questa pagina e non è responsabile del suo contenuto. I termini specificati sono presenti solamente in collegamenti che rimandano alla seguente pagina: allintitle myeloma Lesions of the Palate ,Tongue, Floor of the Mouth Shafa Amirsoltani D.D.S. Lesions of the Palate Torus Palatinus Incisiva Canal Cyst Palatal Abscess Benign Lymphoid Hyperplasia ...

myeloma Instrument No.1 of 1995 REVOKED Statement of Principles concerning MULTIPLE MYELOMA ICD CODE: 203.0 Veterans’ Entitlements Act 1986 subsection 196 B (2) 1. Being of the view that there is sound medical-scientific evidence that indicates that multiple myeloma and death from multiple myeloma can be related to operational service rendered by veterans, peacekeeping service rendered by members of Peacekeeping forces and hazardous service rendered by members of the Forces, the Repatriation Medical Authority determines, under subsection 196B(2) of the Veterans’ Entitlements Act 1986, that the factors that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting multiple myeloma or death from multiple myeloma with the circumstances of that service, are: (a) being within 4 kilometres of the epicentre of the ...

MULTIPLE MYELOMA IN THE RAILROAD INDUSTRY __ R. Dean Hartley Hartley & O'Brien 827 Main Street Wheeling, West Virginia 26003 (304) 233-0777 Telephone (304) 233-0774 Telecopier HNOLAW@HGO.NET I. INTRODUCTION. The word " myeloma " means a tumor of the bone marrow. Most people develop many bone marrow tumors, hence the name "multiple myeloma ." Multiple myeloma is a neoplasm of mature and immature plasma cells. 1 These plasma cells characteristically cause destruction of bone, leading to such troublesome complications as bone pain, compression, fractures, hypercalcemia and renal damage. 2 Abnormal radiographs of the skeleton are found in 80 percent or more of patients at diagnosis. Multiple punched-out osteolytic lesions involving the red bone marrow are typical. 3 Complete remission is rare, and a possible cure has been reported ...

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells Ann-Hwee Lee*, Neal N. Iwakoshi*, Kenneth C. Anderson †‡ , and Laurie H. Glimcher* †§ *Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115-6017; † Department of Medicine, Harvard Medical School, Boston, MA 02115; and ‡ Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected on April 30, 2002. Contributed by Laurie H. Glimcher, June 30, 2003 Novel agents that target the proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, have demonstrated remarkable therapeutic efficacy in multiple my- eloma, ...